文献速递骨软组织肉瘤与黑色素瘤消化系统肿瘤妇科肿瘤

青少年和年轻成人癌症患者的转移性复发研究

Metastatic Recurrence Among Adolescents and Young Adults With Cancer.
PubMed 文献 · JAMA Oncol · 2026-01-01

该回顾性队列研究基于加州癌症登记数据,纳入2006-2018年诊断的15-39岁非转移性癌症患者,估算转移性复发的累积发生率并比较生存。结果显示肉瘤和结直肠癌5年复发率最高,且转移性复发后生存普遍差于初诊即转移者,仅睾丸和甲状腺癌除外。

要点

  • 肉瘤和结直肠癌的5年转移性复发累积发生率最高,分别达24.5%和21.8%。
  • 几乎所有III期癌症(甲状腺除外)的5年复发累积发生率超过30%。
  • 转移性复发后生存差于初诊转移,但睾丸和甲状腺癌例外。

核心结论

  • 青少年和年轻成人癌症患者中转移性复发疾病负担显著,复发后生存多数差于初诊转移。

研究设计与样本

  • 回顾性队列研究,纳入2006-2018年加州癌症登记中15-39岁非转移性癌症患者共43 935例,随访至2020年12月31日。

主要发现

  • 在43 935例非转移性患者中,肉瘤5年转移性复发累积发生率为24.5%(95%CI 22.6%-26.6%),结直肠癌为21.8%(95%CI 20.3%-23.4%)。
  • 宫颈癌5年累积发生率从2006-2009年的12.7%(95%CI 10.8%-14.8%)升至2015-2018年的20.4%(95%CI 17.5%-23.6%)。
  • 结直肠癌5年累积发生率从2006-2009年的24.4%(95%CI 21.3%-27.6%)降至2015-2018年的19.2%(95%CI 16.4%-22.2%)。
  • 除睾丸和甲状腺癌外,所有癌种转移性复发后生存均差于初诊转移者。

临床怎么用

  • 针对肉瘤、结直肠癌等高复发风险的青少年和年轻成人患者,应加强治疗后随访监测。
  • 宫颈癌复发率上升趋势提示需关注该人群的长期管理。

局限性

  • 转移性复发基于ICD编码和死因判定,可能存在漏判或错分。
  • 数据来源于加州单一地区,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite treatment advances, metastatic recurrence continues to be a leading cause of morbidity and mortality. Empirical data on the incidence and survival after metastatic recurrence remain limited, as cancer registries historically do not collect data on recurrence. OBJECTIVE: To estimate the cumulative incidence (CMI) of metastatic recurrence among adolescents and young adults diagnosed with earlier-stage disease and compare survival to those with metastatic disease at diagnosis. DESIGN, SETTING, PARTICIPANTS: This was a retrospective cohort study of adolescents and young adults aged 15 to 39 years who were diagnosed with nonmetastatic cancers from 2006 to 2018. Adolescents and young adults were identified from the California Cancer Registry linked with statewide hospitalization, emergency department, and ambulatory surgery encounters from the California Department of Health Care Access and Information. Data were analyzed from December 2023 to June 2025. EXPOSURES: Cancer types, including melanoma, sarcoma, and breast, cervical, colorectal, testicular, and thyroid cancers. MAIN OUTCOMES AND MEASURES: Metastatic recurrence was identified using International Classification of Diseases, Ninth Revision, Clinical Modification, and Tenth Revision, Clinical Modification, metastatic disease codes at least 6 months after cancer diagnosis or from an underlying cancer cause of death. Follow-up was through December 31, 2020. RESULTS: Of a total of 48 406 adolescents and young adults (median [IQR] age at diagnosis, 33.0 [28.0-37.0] years; 67.4% female), 9.2% had metastatic disease at diagnosis, and 9.5% had metastatic recurrence. Among 43 935 adolescents and young adults who presented with nonmetastatic disease, the 5-year CMI of metastatic recurrences was highest among patients with sarcoma (24.5%; 95% CI, 22.6%-26.6%) and colorectal cancer (21.8%; 95% CI, 20.3%-23.4%) and intermediate for cervical (16.3%; 95% CI, 15.0%-17.6%) and breast (14.7%; 95% CI, 14.0%-15.4%) cancers. The CMI for metastatic recurrence increased with increasing stage at diagnosis, with 5-year CMIs higher than 30% for all stage III cancers (except thyroid). The 5-year CMI of metastatic recurrence also increased over time for cervical cancer (2006-2009: 12.7% [95% CI, 10.8%-14.8%]; 2015-2018: 20.4% [95% CI, 17.5%-23.6%]) and decreased for colorectal cancer (2006-2009: 24.4% [95% CI, 21.3%-27.6%]; 2015-2018: 19.2% [95% CI, 16.4%-22.2%]). Survival after metastatic recurrence was worse than metastatic disease at diagnosis for all cancer types, except for testicular and thyroid cancers. CONCLUSIONS AND RELEVANCE: The findings from this cohort study highlight the overall burden of metastatic disease in adolescents and young adults, expanding the knowledge of metastatic recurrences that help improve care for adolescent and young adult survivors throughout the cancer survivorship spectrum.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Brunson A, Wun T, Abrahão R, et al. Metastatic Recurrence Among Adolescents and Young Adults With Cancer. JAMA Oncol. 2026. PMID: 41296369. doi:10.1001/jamaoncol.2025.4971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。